Zoetis Inc (ZTS)

Currency in USD
120.76
-0.35(-0.29%)
Closed·
120.760.00(0.00%)
·
ZTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
120.20122.47
52 wk Range
113.29172.23
Key Statistics
Prev. Close
120.76
Open
121.74
Day's Range
120.2-122.47
52 wk Range
113.29-172.23
Volume
2.21M
Average Vol. (3m)
4.21M
1-Year Change
-17.716%
Book Value / Share
7.56
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
151.00
Upside
+25.04%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 13 consecutive years

Zoetis Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Employees
14500

Zoetis Inc SWOT Analysis


Future Prospects
Delve into Zoetis's strategies for tapping untapped markets in animal anti-depressants and pain management, while navigating challenges like foreign exchange impacts
Product Innovation
Explore Zoetis's key growth drivers, including Librela for canine osteoarthritis and Apoquel for dermatology, alongside a promising pipeline in oncology and cardiology
Financial Resilience
Analysts project continued growth, with Q3 2024 organic revenue expected to rise 9.2%. Price targets range from $225 to $242, reflecting positive outlook
Market Leadership
Zoetis maintains dominance in animal health, with a robust portfolio spanning companion animal and livestock sectors, despite increasing competition
Read full SWOT analysis

Zoetis Inc Earnings Call Summary for Q4/2025

  • Zoetis reported Q4 2025 EPS of $1.48 (5.71% above forecast) and revenue of $2.4 billion (1.69% above expectations), while returning $3.2 billion to shareholders in 2025.
  • Despite strong earnings, Zoetis shares fell 1.96% in pre-market trading to $126.15, following a 6% drop in the previous session amid market volatility.
  • Full-year 2025 revenue reached $9.5 billion (+2% YoY) with adjusted net income of $2.8 billion (+6% YoY), driven by strong performance in Simparica franchise and diagnostics.
  • CEO Kristin Peck highlighted 'meaningful progress across portfolio and pipeline' as the company projects 3-5% organic revenue growth and 3-6% adjusted net income growth for 2026.
  • Zoetis plans to launch Lenivia in EU and Canada in H1 2026, with FDA approval anticipated in 2027, while addressing competitive pressures in parasiticide and dermatology markets.
Last Updated: 02/12/2026, 10:03 AM
Read Full Transcript
Zoetis Inc investor slides for Q4/2025
Zoetis Q4 2025 slides
Last Update: Feb 12, 2026
See full investor slides

Compare ZTS to Peers and Sector

Metrics to compare
ZTS
Peers
Sector
Relationship
P/E Ratio
19.0x13.8x−0.5x
PEG Ratio
1.890.530.00
Price / Book
15.2x2.0x2.6x
Price / LTM Sales
5.4x2.2x3.2x
Upside (Analyst Target)
20.1%23.9%45.7%
Fair Value Upside
Unlock−3.7%4.8%Unlock

Analyst Ratings

11 Buy
9 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 151.00
(+25.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citi
Buy145.00+20.07%-MaintainApr 15, 2026
Citi
Buy145.00+20.07%-New CoverageApr 15, 2026
Leerink Partners
Hold133.00+10.14%-MaintainMar 10, 2026
Nephron
Hold---DowngradeMar 05, 2026
William Blair
Buy---MaintainMar 02, 2026

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.02%
Dividend Yield
1.75%
Industry Median 2.36%
Annualized Payout
2.12
Paid quarterly
5-Years Growth
+20.11%
Growth Streak

Earnings

Latest Release
Feb 12, 2026
EPS / Forecast
1.48 / 1.40
Revenue / Forecast
2.4B / 2.36B
EPS Revisions
Last 90 days

ZTS Income Statement

People Also Watch

389.72
INTU
+6.25%
61.29
FISV
+3.85%
430.58
SPGI
+1.26%
56.58
MDLZ
-2.18%
244.66
ADBE
+3.79%

FAQ

What Is the Zoetis Inc (ZTS) Stock Price Today?

The Zoetis Inc stock price today is 120.76 USD.

What Stock Exchange Does Zoetis Inc Trade On?

Zoetis Inc is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Zoetis Inc?

The stock symbol for Zoetis Inc is "ZTS."

Does Zoetis Inc Pay Dividends? What’s The Current Dividend Yield?

The Zoetis Inc dividend yield is 1.75%.

What Is the Zoetis Inc Market Cap?

As of today, Zoetis Inc market cap is 50.78B USD.

What Is Zoetis Inc's Earnings Per Share (TTM)?

The Zoetis Inc EPS (TTM) is 6.02.

When Is the Next Zoetis Inc Earnings Date?

Zoetis Inc will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is ZTS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Zoetis Inc Stock Split?

Zoetis Inc has split 0 times.

How Many Employees Does Zoetis Inc Have?

Zoetis Inc has 14500 employees.

What is the current trading status of Zoetis Inc (ZTS)?

As of Apr 16, 2026, Zoetis Inc (ZTS) is trading at a price of 120.76 USD, with a previous close of 120.76 USD. The stock has fluctuated within a day range of 120.20 USD to 122.47 USD, while its 52-week range spans from 113.29 USD to 172.23 USD.

What Is Zoetis Inc (ZTS) Price Target According to Analysts?

The average 12-month price target for Zoetis Inc is 151.00 USD, with a high estimate of 190 USD and a low estimate of 130 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +25.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.